HC Wainwright Lowers SAB Biotherapeutics (NASDAQ:SABS) Price Target to $7.00

SAB Biotherapeutics (NASDAQ:SABS) had its price objective lowered by HC Wainwright from $9.00 to $7.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 82.29% from the stock’s current price.

SABS has been the subject of several other reports. Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Chardan Capital reissued a “buy” rating and issued a $12.00 price target on shares of SAB Biotherapeutics in a report on Thursday, December 18th. Guggenheim started coverage on shares of SAB Biotherapeutics in a research report on Friday, December 19th. They issued a “buy” rating and a $15.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Finally, UBS Group started coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

SAB Biotherapeutics Trading Up 1.3%

SABS stock opened at $3.84 on Tuesday. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. The firm has a market cap of $182.82 million, a P/E ratio of -1.24 and a beta of 0.59. The company’s 50-day simple moving average is $3.97 and its 200-day simple moving average is $3.32.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter. As a group, equities analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SABS. Vivo Capital LLC acquired a new stake in SAB Biotherapeutics during the third quarter worth about $22,954,000. Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter valued at approximately $8,847,000. RA Capital Management L.P. acquired a new position in SAB Biotherapeutics in the third quarter valued at approximately $8,847,000. Woodline Partners LP acquired a new stake in SAB Biotherapeutics during the third quarter worth $5,730,000. Finally, Spruce Street Capital LP purchased a new stake in SAB Biotherapeutics in the fourth quarter valued at $8,222,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.